Inclusion Criteria:  Aged 18-80 years old; Cerebellar hemorrhage was confirmed by computed tomography (CT) scans; The hematoma was > 3 cm in diameter or the hematoma volume was > 10ml or the hemorrhage is associated with brainstem compression or hydrocephalus; The randomization can be conducted within 24 hours; GCS score at randomization was 5-14; mRS was 0-1 before onset; The systolic pressure was controlled below 180 mmHg before randomization; Informed consent was obtained from the patient and his legal representative.  Exclusion Criteria:  Coexistent intracranial bleeding from other sites; Brain herniation before randomization; Bleeding caused by other reasons such as aneurysm, arteriovenous malformation, trauma, and tumor; hemorrhage secondary to large cerebral infarction, beta-amyloid degeneration disease, or coagulation dysfunction; coexistent aneurysm, arteriovenous malformation, brain trauma, brain tumors, large area cerebral infarction, beta-amyloid degeneration disease, or serious blood coagulation disorders; A history of cerebral hemorrhage within 1 year; A history of intracranial surgery or hemorrhagic disease (intracerebral hemorrhage, subarachnoid hemorrhage, subdural or epidural hemorrhage) within the last 30 days; Hemoglobin < 100g/L, hematocrit < 25%, platelet count <100*10^9/L; Warfarin, dabigatran, rivaroxaban, and other anticoagulant drugs were given within one week before enrollment, and the INR was > 1.4; Aspirin, clopidogrel, ticagrelor, and other antiplatelet drugs were given within one week before enrollment, and the inhibition rate of AA-dependent pathway > 50%，inhibition rate of ADP-dependent pathway > 30%; Long-term anticoagulation and antiplatelet therapy is needed; A history of internal bleeding that is not completely controlled, such as gastrointestinal bleeding, genitourinary bleeding, respiratory bleeding; Myocardial infarction within 30 days; Patients with high risks of embolization (a history of mechanical heart valve implantation, left ventricular thrombosis, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis); atrial fibrillation without mitral stenosis is acceptable; Severely impaired liver function (ALT > 3 times the normal upper limit, or AST > 3 times the normal upper limit); severely impaired renal function (glomerular filtration rate < 30ml/min/1.73m2); Hypertension could not be effectively controlled before randomization (systolic blood pressure ≥ 180 mmHg); Patients cannot complete the follow-up due to Alzheimer's disease or mental illness; Coexistent serious diseases of the respiratory, circulatory, digestive, urogenital, endocrine, immune, and blood systems that are likely to interfere with the results; Patients with current drug/alcohol abuse or dependence, or expected to have poor compliance and difficult to complete the follow-up; Allergic to the drugs or instruments used in surgery; Patients with surgery contraindications, or the other factors that may preclude implementation of the study protocol; Pregnant or lactating women; Life expectancy < 12 months due to any advanced stage of disease; Patient is participating in other clinical trials; The legal guardian of the patient is unwilling to sign the written informed consent; Assessed unsuitable for inclusion by investigators.